Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 2Lung Neoplasms 2Non-Small Cell Lung Cancer ALK-positive 1Neurofibromatosis 1 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lymphoma, Large-Cell, Anaplastic 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Bevacizumab 57Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 33Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15HMPL-013 13Folfox protocol 13Cisplatin 13Capecitabine 13trifluridine tipiracil drug combination 12Panitumumab 12Gemcitabine 12Carboplatin 12Pemetrexed 10IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Trifluridine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × lorlatinib × 90 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡